Developing an oncology portfolio of anticancer drugs: the experience of one pharmaceutical company.
For a company or institute that wishes to develop new anti-cancer agents, it is necessary to establish a portfolio of agents to reduce the risk of failure. Success rates for developing new agents are low and therefore different biological effect areas should be explored to ensure that at least one agent targeting cancer or a specific histological sub-type of cancer is effectively developed. This paper describes how one pharmaceutical company has developed a range of different agents with the ultimate aim of developing as many of these as is technically feasible into useful new medicines for the treatment of cancer.
Blackledge
G R
GR
AstraZeneca Pharmaceuticals, Macclesfield, UK. George.Blackledge@astrazeneca.com
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000145:classification* / Q000627:therapeutic use*; D004019:Dictionaries, Pharmaceutic as Topic; D020249:Hormone Replacement Therapy; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents